China Oncology to develop and commercialize Sorrento’s anti-PD-L1 antibody
As part of the deal, Lee’s Pharma will have exclusive rights to develop and commercialize the antibody for the Chinese market, including Mainland China, Hong Kong, Macau, and
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.
The facility will be used to support automated production of the company’s Arcelis-based personalized immunotherapy product candidates, beginning with AGS-003, the company’s lead oncology product candidate, currently being
The humanized monoclonal antibody, RPC4046 is directed against interleukin-13 (IL-13), a target which has been validated in other related allergic indications. Receptos president and chief executive officer Faheem